Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

2019 February 26 - 28
Hilton Tokyo Bay Hotel,
Tokyo, Japan

The Only Event in Asia Providing the Latest Science, Technology and Partners to Accelerate Antibody & Protein Therapies, ADCs, Bispecifics and Immuno-Oncology

World-renowned scientists sharing the latest technologies, R&D and clinical data to fast-track your next-generation therapeutics towards commercial success

Want to speak at Antibody Engineering & Therapeutics Asia?

  • Clinical and preclinical data from antibodies in development: Lessons learned
  • Bispecific antibody discovery and development
  • ADC (Antibody-drug conjugate) discovery and development
  • Immunotherapies, immune checkpoints and immuno-oncology
  • Novel antibody targets and target validation (i.e. ion channels and GPCRs)
  • Antibody therapeutics for non-cancer indications
  • Antibody therapeutics in cancer and Immuno-oncology
  • Antibodies for CAR-T/TCR Therapies
  • Novel antibody display, selection and screening approaches
  • “Developability” and “manufacturability” of antibodies
  • Internalizing and penetrating antibodies, Overcoming antibody delivery challenges
  • Engineering antibodies for improved drug-like properties
  • Computational and experimental tools for antibody discovery and development
  • Next-generation sequencing for finding better binders
  • Combination antibody therapies
  • New antibody-like formats like trimerics and cytokine-linked Abs and other formats

Antibody Engineering & Therapeutics ASIA Scientific Advisory Board

  • Tomoyuki Igawa, Ph.D., CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
  • Osamu Sam Sato, Ph.D., Executive Director, R&D Planning Department, Daiichi Sankyo Co., Ltd., Japan
  • Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH
  • Jijie Gu, Ph.D., Head of Target Validation, Immunology Discovery, Abbvie Cambridge Research Center, USA
  • Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering, Ajou University, South Korea
  • Qing Li, Ph.D., Scientist I, MedImmune, USA
  • Karthik Viswanathan, Director, Research, Visterra, Inc., USA
  • Chengbin Wu, Ph.D., Chief Executive Officer, EpimAb Biotherapeutics Inc., China